Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Withdrawn × Carcinoid Heart Disease × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 23 Neoplasms 17 Prostatic Neoplasms 14 Carcinoma, Non-Small-Cell Lung 12 Carcinoma, Hepatocellular 10 Head and Neck Neoplasms 8 Urinary Bladder Neoplasms 7 Pain 7 Ovarian Neoplasms 7 Leukemia, Myeloid, Acute 7 Squamous Cell Carcinoma of Head and Neck 6 Neoplasm Metastasis 6 Lung Neoplasms 6 Lymphoma, Follicular 5 Leukemia 5 Brain Neoplasms 5 Uterine Cervical Neoplasms 4 Stomach Neoplasms 4 Small Cell Lung Carcinoma 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Lymphoma, Non-Hodgkin 4 Lymphoma 4 Carcinoma 4 Urogenital Neoplasms 3 Papillomavirus Infections 3 Pancreatic Neoplasms 3 Non-Muscle Invasive Bladder Neoplasms 3 Melanoma 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡